focus
The Food and Drug Administration on Thursday approved the first medicine developed specifically to treat the serious liver disease known as MASH.
The pill, called Rezdiffra, is made by Madrigal Pharmaceuticals.
advertisement
Metabolic dysfunction-associated steatohepatitis, or MASH, is often associated with obesity. The accumulation of fat in the liver causes inflammation, which leads to fibrosis, or liver scarring, and can progress in more advanced stages to cirrhosis, cancer, and the need for a liver transplant.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Sage considers ways to reduce costs following FDA rejection
Next article： New air purifier tech could be key to improving indoor air quality
Next article： New air purifier tech could be key to improving indoor air quality
